NOT FOR DIRECT OR INDIRECT PUBLICATION, DISTRIBUTION OR DISSEMINATION IN THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN

PRESS RELEASE

CARMAT FILES A CLINICAL TRIAL APPLICATION WITH THE FRENCH HEALTH AUTHORITIES FOR ITS ARTIFICIAL HEART

Achievement of a key milestone on the road to the first implantation in man in late 2011

Paris, July 12, 2011

CARMAT (FR0010907956, ALCAR), the designer and developer of the world's most advanced total artificial heart, today announced that thanks to progress made over the last few months, it has filed a clinical trial application with the French Agency for Safety Sanitary of the Healthcare Products Safety (AFSSAPS, *Agence Française de Sécurité Sanitaire des Produits de Santé*), with a view to the first clinical trials in man (scheduled for late 2011).

CARMAT CEO Marcello Conviti commented: *"In view of our recent progress, we are confident of achieving our objective (the first implantation in man of our artificial heart) before the end of 2011, subject to authorisation by the AFSSAPS and approval by the independent ethics committees."*

CARMAT CSO Professor Alain Carpentier added: *"The results of tests carried out on an integrated version of the CARMAT total artificial heart have further strengthened my confidence in our device – a real solution to the challenging problem of treating end-stage heart failure patients who are not medically eligible for cardiac assist devices. These results have prompted us to start preparing the second phase of our clinical development programme, which will seek to improve patients' personal independence and quality of life".*

CARMAT has taken advantage of a fast-track procedure for innovative technologies which enables the submission of a preliminary application and then completion of the latter as the data becomes available. The company expects to receive a reply from the AFSSAPS (concerning permission to set up and perform the first clinical trials) in Q4 2011.

Approval by independent ethics committees will be requested in parallel with the AFSSAPS authorization.

NOT FOR DIRECT OR INDIRECT PUBLICATION, DISTRIBUTION OR DISSEMINATION IN THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN

About CARMAT: CARMAT, the world's most advanced total artificial heart

The only credible response for all cases of end-stage heart failure - a true public health issue. CARMAT's ultimate aim is to provide a response to a major public health issue associated with cardiovascular disease, the world's leading cause of death: heart failure. This disease currently affects over 20 million patients in Europe and the United States. By pursuing the development of its total artificial heart, CARMAT intends to overcome the well-known shortfall in heart transplants for the tens of thousands of people suffering from end-stage heart failure.

The result of combining two types of unique expertise: the medical expertise of Professor Carpentier, known throughout the world for inventing Carpentier-Edwards® heart valves - most widely used worldwide - and the technological expertise of EADS, a global aerospace leader.

Imitating the natural heart. Given its size and weight, the choice of structural materials and its innovative physiological functions, CARMAT's total artificial heart could, assuming upcoming clinical trials are successful, potentially benefit tens of thousands of patients a year – with no risk of rejection and providing them with unparalleled quality of life.

A project leader acknowledged at the European level: with the backing of the European Commission, CARMAT has received the largest grant-in-aid (a total of €33 million) made to an SME by OSEO (the French state innovation agency).

Strongly committed, prestigious founders and shareholders: Truffle Capital (the leading European venture capital firm), EADS, the Foundation Alain Carpentier and thousands of institutional and individual shareholders have placed their trust in CARMAT.

For more information, visit www.carmatsa.com

Risk factors. CARMAT wishes to draw the reader's attention to the "risk factors" section of the prospectus approved by the *Autorité des marches financiers* (the French stock market regulator). These risk factors are detailed in chapter 4 of the reference document and section 2 of the operating note.

NOT FOR DIRECT OR INDIRECT PUBLICATION, DISTRIBUTION OR DISSEMINATION IN THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN

This press release and the information contained herein does not constitute or form part of, and should not be constituted as, an offer or invitation to sell or subscribe for, or a solicitation of any offer or invitation to acquire, dispose of or subscribe for, shares in Carmat ("the Company") in any country. The publication of this press release in certain countries may violate applicable regulations. With respect to the member states of the European Economic Area which have implemented the Directive 2003/71/EC of the European Parliament and the Council of November 4, 2003 (the "Prospectus Directive"), other than France, no action has been undertaken or will be undertaken to make an offer to the public of the Carmat securities requiring a publication of a prospectus in any relevant member state (other than France). As a result, the securities may not and will not be offered in any relevant member state (other than France) except in accordance with the exemptions set forth in Article 3(2) of the Prospectus Directive, if they have been implemented in that relevant member state, or under any other circumstances which do not require the publication by Carmat of a prospectus pursuant to Article 3 of the Prospectus Directive and/or to applicable regulations of that relevant member state. The information contained therein does not constitute an offer for securities in the United States, Canada, Australia or Japan or in any other jurisdiction. This press release should not be published, transmitted or distributed, directly or indirectly, into the United States, Canada, Australia or Japan. This press release is not an offer for sale or a solicitation of offers to purchase CARMAT securities in the United States. The securities of CARMAT may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. CARMAT does not intend to register any portion of an offering in the United States or to conduct a public offering of securities in the United States. This press release does not constitute an invitation or inducement to engage in investment activity under section 21 of the Financial Services and Markets Act 2000 and is for distribution only to persons who (A) are outside the United Kingdom, or (B) are qualified investors as described in section 86(7) of the Financial Services and Markets Act 2000 (being persons falling within Article 2.1(e)(i), (ii) or (iii) of Directive 2003/71/EC) and (i) have professional experience in matters relating to investments falling within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"), or (ii) are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations etc") of the Order, or (iii) to whom it may otherwise be lawfully communicated (all such persons together being referred to as "relevant persons"). This press release is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this press release relates is available only to relevant persons. This press release contains forward-looking statements. No guarantee can be given as to any of the events anticipated by the forward-looking statements, which are subject to inherent risks, including those described in the Document de Référence registered with the Autorité des Marchés Financiers under number R.11-017 on 27 April 2011 and the Note d'Opération that was approved by the Autorité des Marchés Financiers on 11 July 2011, changes in economic conditions, the financial markets or the markets in which CARMAT operates.

CARMAT
Marcello Conviti
CEO
Patrick Coulombier
COO
Valerie Leroy
Marketing and Investor Relations Director
Tel. : +33 139 456450
investors@carmatsa.com

NewCap
Financialcommunication and investor relations
Axelle Vuillermet / Emmanuel Huynh

Tel.: +33 144 719494
carmat@newcap.fr

Alize RP
Press relations
Caroline Carmagnol

+33 6 64 18 99 59
caroline@alizerp.com

ALCAR LISTED NYSE ALTERNEXT

Name: **CARMAT**
ISIN code: **FR0010907956**
Ticker: **ALCAR**